Market revenue in 2023 | USD 179.2 million |
Market revenue in 2030 | USD 314.0 million |
Growth rate | 8.3% (CAGR from 2023 to 2030) |
Largest segment | Anti- inflammatories |
Fastest growing segment | Combination therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti- inflammatories, Bronchodilators, Combination therapy |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, GSK PLC, Merck & Co Inc, Roche Holding AG, AstraZeneca PLC, Boehringer Ingelheim, Sanofi SA, Koninklijke Philips NV, BD, Corvus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to asthma therapeutics market will help companies and investors design strategic landscapes.
Anti- inflammatories was the largest segment with a revenue share of 62.05% in 2023. Horizon Databook has segmented the Saudi Arabia asthma therapeutics market based on anti- inflammatories, bronchodilators, combination therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Saudi Arabia’s asthma therapeutics market is estimated to exhibit significant growth over the forecast period due to new product launches and increasing favorable government initiatives. For instance, in September 2020, on the pretext of respiratory problems due to dust storms, the Health Ministry advised people with asthma to cover their head, mouth, & nose outdoors and to use a bronchodilation atomizer.
As per the Global Asthma Report in 2022, asthma is currently ranked 34th among the leading contributors to the burden of disease, and the prevalence of diagnosed asthma in adults has increased from 4% to 11%.
Furthermore, in Saudi Arabia, COPD affects around 4.2% of the general population and 14.5% of the smoking population. Smoking rates in Saudi Arabia are 27.9%, and the country’s dusty climate is one of the major risk factors for COPD, and the treatment of respiratory disorders is insufficient.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia asthma therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia asthma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account